

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the People's Republic of China or elsewhere.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

VOLUNTARY ANNOUNCEMENT

PROGRESS ON THE SUBSEQUENT LISTING OF SICHUAN RUIJIAN MEDICAL ON BEIJING STOCK EXCHANGE

This announcement is made by PW Medtech Group Limited (the “**Company**”) on a voluntary basis.

Reference is made to (i) the relevant announcements of the Company dated May 20, 2024, July 2, 2024, October 2, 2024, December 5, 2024, December 9, 2024, March 25, 2025 and June 20, 2025; (ii) the circular of the Company dated January 21, 2025 (the “**Circular**”); and (iii) the overseas regulatory announcement of the Company dated April 30, 2025, in relation to, among others, the possible major transaction and deemed disposal in relation to the proposed listing of Sichuan Ruijian Medical. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular. As disclosed in the Circular, the NEEQS Quotation was approved by the NEEQ Co., Ltd. and was successfully completed. Further, as disclosed in the relevant announcement of the Company dated March 25, 2025, Sichuan Ruijian Medical has submitted its application for the Subsequent Listing to the Beijing Stock Exchange on the same day. The Board hereby provides the latest update on the Subsequent Listing to its Shareholders.

As disclosed in the announcement of the Company dated June 20, 2025, on June 19, 2025, Sichuan Ruijian Medical submitted an application to the Beijing Stock Exchange voluntarily for the suspension of the Subsequent Listing’s review process, and the review status of the Subsequent Listing has been adjusted by the Beijing Stock Exchange to suspension of review accordingly. **On August 7, 2025, Sichuan Ruijian Medical submitted an application to the Beijing Stock Exchange to resume the review process. As at the date of this announcement, the review status of the Subsequent Listing has been adjusted by the Beijing Stock Exchange to resumption of review.** Further announcement(s) will be made by the Company in accordance with the Listing Rules as and when appropriate.

Shareholders and potential investors should note that the Subsequent Listing is subject to, among other things, the prevailing market conditions and approvals from relevant authorities, including the CSRC and the Beijing Stock Exchange. Accordingly, Shareholders and potential investors should be aware that the Company does not guarantee that the Subsequent Listing will materialize, nor the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, August 11, 2025

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.